Amneal Pharmaceuticals, Inc. (AMRX) FY2026 Q2 Balance Sheet

Amneal Pharmaceuticals, Inc. (AMRX) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets

3,776,348,000 US dollars

Current assets

1,947,029,000 US dollars

Non-current assets

1,829,319,000 US dollars

Liabilities (calculated)

3,659,368,000 US dollars

Current liabilities

883,187,000 US dollars

Non-current liabilities

2,776,181,000 US dollars

Equity

33,024,000 US dollars

Redeemable non-controlling interests

83,956,000 US dollars

Noncontrolling interest

0 US dollars. Included in consolidated equity; this amount is not added again.

Receivables - Nonrelated Party

1,020,360,000 US dollars

Inventories

677,954,000 US dollars

Cash and cash equivalents

127,637,000 US dollars

Prepaid expenses and other current assets

112,011,000 US dollars

Restricted cash

8,643,000 US dollars

Receivables - Related Party

424,000 US dollars

Goodwill

593,499,000 US dollars

Intangible assets, net

587,830,000 US dollars

Property, plant and equipment, net

456,877,000 US dollars

Other assets

80,669,000 US dollars

Financing lease right-of-use assets - Nonrelated Party

52,360,000 US dollars

Operating lease right-of-use assets - Nonrelated Party

44,361,000 US dollars

Operating lease right-of-use assets - Related Party

13,723,000 US dollars

Accounts payable and accrued expenses - Nonrelated Party

721,208,000 US dollars

Revolving credit facility

100,000,000 US dollars

Accounts payable and accrued expenses - Related Party

22,070,000 US dollars

Current portion of liabilities for legal matters

18,488,000 US dollars

Current portion of operating lease liabilities - Nonrelated Party

9,040,000 US dollars

Current portion of long-term debt, net

5,961,000 US dollars

Current portion of financing lease liabilities - Nonrelated Party

3,521,000 US dollars

Current portion of operating lease liabilities - Related Party

2,899,000 US dollars

Long-term debt, net

2,564,335,000 US dollars

Liabilities for legal matters - long term

70,830,000 US dollars

Financing lease liabilities - Nonrelated Party

54,602,000 US dollars

Operating lease liabilities - Nonrelated Party

38,691,000 US dollars

Related party payables - long term - Nonrelated Party

32,119,000 US dollars

Operating lease liabilities - Related Party

12,712,000 US dollars

Related party payables - long term - Related Party

2,892,000 US dollars

Additional paid-in capital

545,584,000 US dollars

Common stock - Common Class A

3,193,000 US dollars

Preferred stock, $0.01 par value, 2,000 shares authorized at both June 30, 2026 and December 31, 2025; none issued at both June 30, 2026 and December 31, 2025

0 US dollars

Common stock - Common Class B

0 US dollars

Non-controlling interests

0 US dollars

Stockholders’ accumulated deficit

negative 415,087,000 US dollars

Accumulated other comprehensive loss

negative 100,666,000 US dollars

Gross equity (calculated)

548,777,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

• Assets equal liabilities plus temporary equity plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
• Treasury shares and other negative equity contributions reduce equity.